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Sumoylation is a post-translational modification affect-
ing diverse cellular processes including DNA replication
and repair, chromosome packing and dynamics, genome
integrity, nuclear transport, signal transduction and cell
proliferation [1]. Sumoylation involves the covalent
attachment of a small ubiquitin like modifier (SUMO)
protein to ε-amino group of lysine residues in specific
target proteins via a sequential action of an activating
enzyme E1 (SUMO E1), a conjugating enzyme E2 and a
ligase E3. Among the sumoylation proteins, SUMO E1
is responsible for the activation of SUMO in the first step
of the sumoylation cascade [2]. SUMO E1 is linked to
many human diseases including cancer and thus making it
a potential therapeutic target [3]. However, only a few
inhibitors were reported up to now that includes three
natural products, semi-synthetic protein inhibitors and
one AMP mimic [4-6]. Here in this research, the combina-
tion of structure based virtual screening and in vitro
sumoylation assay was used to identify potential small
molecule inhibitors of SUMO E1 that could be used in
chemical biology and therapeutic studies. Our virtual
screening protocol involves the fast docking of a small
molecule library to rigid protein followed by redocking of
top hits using a method that incorporates both ligand and
protein flexibility. Subsequently, the top ranking com-
pounds were prioritized using molecular dynamics simula-
tion based binding free energy calculation. The result of
biological assay and subsequent similarity search resulted
in the identification of two classes of small molecules that
shared biaryl urea scaffold. Both of these chemical classes
displayed moderate inhibitory potency against SUMO E1.
The most potent compound of each class inhibited the in
vitro sumoylation with an IC50 of 11.1 and 13.4 μM. These
compounds inhibit sumoylation by blocking the formation
of SUMO-E1 thioester intermediate. Our study presents
starting points for the development of novel therapeutic
agents against various diseases targeting SUMO E1.
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